Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 72603-882

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 72603-882). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

956 (Sacubitril Valsartan 24 mg 26 mg 180 Baddi)

This text contains information about a medication called Sacubitril and Valsartan Tablets. Each film-coated tablet contains 24 mg of sacubitril and 26 mg of valsartan. The recommended dosage and storage instructions are provided, along with details about the manufacturer (Macleods Pharmaceuticals Ltd.) and distributor (Northstar Rx LLC). The product is manufactured in India.*

FDA Label Image

541 (Sacubitril Valsartan 24 mg 26 mg 180 Indore)

Each film-coated tablet contains 24 mg of sacubitril and 26 mg of valsartan. The usual dosage should be followed as per the prescribing information for Sacubltril. Store the tablets at a temperature of 20° to 25°C (68° to 77°F) with excursions to 15° to 30°C (59° to 86°F) permitted. Protect from moisture and keep out of the reach of children. This product is manufactured for Northstar Rx LLC by Macleods Pharmaceuticals Ltd. This tablet is a product of India.*

FDA Label Image

879 (Sacubitril Valsartan 24 mg 26 mg 60 Baddi)

Each film-coated tablet contains 24 mg of sacubitril and 26 mg of valsartan. The usual dosage is specified in the prescribing information. These tablets should be stored at temperatures between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F) as per USP Controlled Room Temperature guidelines to protect them from moisture. Keep them out of the reach of children. This product is manufactured by Macleods Pharmaceuticals Ltd. for Northstar Rx LLC in India.*

FDA Label Image

546 (Sacubitril Valsartan 24 mg 26 mg 60 Indore)

This text provides information about a medication with the NDC code 72603-880-01. It is a combination tablet containing Sacubitril and Valsartan in the strength of 24 mg/26 mg. Each film-coated tablet contains the mentioned ingredients. The typical dosage should be referred to the prescribing information. The tablets should be stored at 20° to 25°C and protected from moisture. The product is manufactured in India by Northstar Rx LLC and Macleods Pharmaceuticals Ltd. The tablets come in a container of 60 tablets.*

FDA Label Image

856 (Sacubitril Valsartan 49 mg 51 mg 180 Baddi)

These tablets contain a combination of sacubitril and valsartan, each film-coated tablet consists of 49 mg of sacubitril and 51 mg of valsartan. The standard dosage information is available in the prescribing information. They should be stored at 20° to 25°C with excursions permitted to 15° to 30°C. It is essential to protect the tablets from moisture and keep them out of reach of children. This product is manufactured by Macleods Pharmaceuticals Ltd in India for Northstar Rx LLC based in Memphis, Tennessee.*

FDA Label Image

985 (Sacubitril Valsartan 49 mg 51 mg 180 Indore)

This is a description of a medication containing 49 mg of sacubitril and 51 mg of valsartan in each film-coated tablet. The tablets are stored at 20° to 25°C, with excursions permitted to 15° to 30°C. It is advised to protect the tablets from moisture and keep them out of the reach of children. The product is manufactured by Macleods Pharmaceuticals Ltd. in India for Northstar Rx LLC in Tennessee. The NDC (National Drug Code) for this medication is 72603-881-02. The usual dosage instructions are not available in the provided text.*

FDA Label Image

520 (Sacubitril Valsartan 49 mg 51 mg 60 Baddi)

This text provides information about a medication with the NDC code 72603-881-01 containing sacubitril and valsartan. Each film-coated tablet includes 49 mg of sacubitril and 51 mg of valsartan. It also gives storage instructions, dosage guidance, and details about the manufacturer which is Northstar Rx LLC, with the tablets being manufactured by Macleods Pharmaceuticals Ltd. The medication is a product of India.*

FDA Label Image

336 (Sacubitril Valsartan 49 mg 51 mg 60 Indore)

This is a description for a film-coated tablet containing 49 mg of sacubitril and 51 mg of valsartan. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). The tablets should be protected from moisture and kept out of the reach of children. The product is manufactured by Macleods Pharmaceuticals Ltd. in India for Northstar Rx LLC in Memphis, TN.*

FDA Label Image

564 (Sacubitril Valsartan 97 mg 103 mg 180 Baddi)

Each film-coated tablet contains 97 mg of sacubitril and 103 mg of valsartan. This medication is typically used for treating certain heart conditions. The usual dosage should be followed as per the prescribing information. Store the tablets in a cool, dry place at a temperature between 59°F to 86°F. Make sure to protect them from moisture and keep them out of reach of children. The product is manufactured in India by Macleods Pharmaceuticals Ltd for Northstar Rx LLC.*

FDA Label Image

848 (Sacubitril Valsartan 97 mg 103 mg 180 Indore)

This is a description of a medication in the form of film-coated tablets containing 97 mg of sacubitril and 103 mg of valsartan. The usual dosage information for sacubitril is found in the prescribing information. The tablets should be stored at room temperature, away from moisture and out of reach of children. The medication is manufactured by Northstar Rx LLC for Macleods Pharmaceuticals Ltd in India.*

FDA Label Image

123 (Sacubitril Valsartan 97 mg 103 mg 60 Baddi)

This is a description for a medication containing Sacubitril and Valsartan in tablet form. Each film-coated tablet contains 97 mg of sacubitril and 103 mg of valsartan. The usual dosage should be followed as per the prescribing information. It is advised to store the tablets at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F). Protection from moisture is necessary, and they should be kept out of the reach of children. This medication is manufactured for Northstar Rx LLC and is a product of India, manufactured by Macleods Pharmaceuticals Ltd.*

FDA Label Image

456 (Sacubitril Valsartan 97 mg 103 mg 60 Indore)

Each film-coated tablet contains 97 mg of sacubitril and 103 mg of valsartan. The usual dosage and storage instructions are mentioned on the packaging. Keep the tablets at 20° to 25°C (68° to 77°F) and protect them from moisture. Manufactured for Northstar Rx LLC by Macleods Pharmaceuticals Ltd. in India. The product details including NDC number, expiration date, and manufacturer information are provided on the packaging.*

FDA Label Image

778 (Sacubitril Valsartan Figure 1)

FDA Label Image

232 (Sacubitril Valsartan Figure 2)

FDA Label Image

414 (Sacubitril Valsartan Figure 3a)

This text provides data on the Time to First Occurrence of CV Death or Heart Failure Hospitalizations in the PARADIGM-HF study. The results indicate a significant difference with p<0.0001 between Sacubitril and valsartan versus enalapril. The hazard ratio (HR) with a 95% confidence interval (CI) for Sacubitril and valsartan was 0.80 (0.73, 0.87). The failure rate (%) for each treatment group is presented graphically over time. The number at risk and time since randomization in days are also depicted for both Sacubitril & Valsartan and Enalapril groups.*

FDA Label Image

654 (Sacubitril Valsartan Figure 3b)

This is a chart showing the Time to Occurrence of Cardiovascular (CV) Death in the PARADIGM-HF clinical trial comparing Enalapril and Sacubitril with Valsartan. The chart displays the failure rate (%) over time for both treatments and also provides data on the number at risk and time since randomization in days.*

FDA Label Image

456 (Sacubitril Valsartan Figure 4)

The text provides a detailed breakdown of the population in a study comparing Sacubitril & Valsartan to Enalapril based on different factors like age, gender, weight, race, NYHA class, diabetes, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, hospitalization history, time since diagnosis, and cause of heart failure. The Hazard Ratio is also provided for each subgroup. The study concludes that Sacubitril & Valsartan seems to outperform Enalapril in most cases.*

FDA Label Image

478 (Sacubitril Valsartan Figure 5)

FDA Label Image

456 (Sacubitril Valsartan Figure 6)

This dataset presents subgroup information related to a clinical study comparing the efficacy of Sacubitril & Valsartan and Valsartan in a specific population. The subgroups are categorized based on age, gender, race, region, diabetic status, LVEF, AF based on ECG, AF based on history, NT-proBNP levels, SBP levels, use of MRA, ACEI intolerance, eGFR, and NYHA classification at baseline. The study also provides outcomes in terms of rate ratio estimates, with confidence intervals, indicating which treatment might be more effective in different subgroups.*

FDA Label Image

412 (Sacubitril Valsartan Figure 7)

This is a comparison table showing the left ventricular ejection fraction at screening for the studies PARADIGM-HF and PARAGON-HF. The table compares sacubitril and valsartan versus enalapril for PARADIGM-HF and sacubitril and valsartan versus valsartan for PARAGON-HF. The data includes various ejection fractions ranging from 16% to 5%.*

FDA Label Image

Str (Sacubitril Valsartan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.